Immuneering (IMRX) Free Cash Flow (2020 - 2026)

Immuneering's Free Cash Flow history runs 7 years deep, the most recent figure standing at -$18.5 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 31.4% year-over-year to -$18.5 million in Q1 2026; TTM through Mar 2026 was -$49.9 million, a 6.96% increase from a year earlier, with the FY2025 full-year figure at -$45.5 million, up 17.42% from the prior year.
• Free Cash Flow retreated to -$18.5 million in Q1 2026 per IMRX's latest filing, from -$10.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$9.4 million in Q2 2025 and bottomed at -$18.5 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$12.0 million (2025), against an average of -$12.5 million.
• Across the five-year window, Free Cash Flow plunged 101.35% in 2022 and jumped 31.37% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$11.8 million in 2022, then decreased by 1.08% to -$11.9 million in 2023, then declined by 21.54% to -$14.5 million in 2024, then soared by 31.37% to -$10.0 million in 2025, then sank by 85.79% to -$18.5 million in 2026.
• Per Business Quant, the three latest IMRX Free Cash Flow figures stand at -$18.5 million (Q1 2026), -$10.0 million (Q4 2025), and -$12.0 million (Q3 2025).